CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M, Inoue A, Ohnishi T, Yano H, Kanemura Y, Kohno S, Ohue S, Ozaki S, Matsumoto S, Suehiro S, Nakamura Y, Shigekawa S, Watanabe H, Kitazawa R, Tanaka J, Kunieda T.
Nishikawa M, et al. Among authors: kanemura y.
Cancer Med. 2021 Mar;10(6):2013-2025. doi: 10.1002/cam4.3767. Epub 2021 Feb 5.
Cancer Med. 2021.
PMID: 33543833
Free PMC article.